Cold Agglutinin Disease Real World Evidence Registry

计划入组 429 人 · 首次发布于 2023 年 3 月 30 日

Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan

计划入组 7 人 · 首次发布于 2021 年 11 月 24 日

A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion

计划入组 42 人 · 首次发布于 2017 年 11 月 20 日

Sutimlimab(Enjaymo)

DCUK OMe

Homocystinuria(Tome Biosciences)

Wuyts Joke

Belgium

ARKANSAS HOME MEDICAL

United States

HOME HEALTH DEPOT

United States

Real-World Safety Data Confirms Long-Term Tolerability of ENJAYMO in Cold Agglutinin Disease Patients

Low-Dose Rituximab Trial Shows Limited Efficacy in Cold Agglutinin Disease Patients

Recordati Rare Diseases Presents Nine Research Studies on Rare Hematologic Disorders at ASH 2025